Discovery of an ellipticine derivative as TLR3 inhibitor against influenza A virus and SARS-CoV-2
- 21 February 2024
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 101, 129672
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82073897)
- National Natural Science Foundation of China (82073689)
- National Natural Science Foundation of China (82273762)
- Natural Science Foundation of Guangdong Province (2018B030312010)
- National Key Research and Development Program of China
- Guangzhou Municipal Science and Technology Program key projects (201904010380)
- Key Technologies Research and Development Program (2022YFC2304203)
This publication has 25 references indexed in Scilit:
- Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug TargetCurrent Topics in Medicinal Chemistry, 2017
- The inflammatory response triggered by Influenza virus: a two edged swordInflammation Research, 2016
- Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015Antiviral Research, 2016
- New small-molecule drug design strategies for fighting resistant influenza AActa Pharmaceutica Sinica B, 2015
- Peptide entry inhibitors of enveloped viruses: The importance of interfacial hydrophobicityBiochimica et Biophysica Acta (BBA) - Biomembranes, 2014
- Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2Journal of Medicinal Chemistry, 2014
- Pattern recognition receptors in innate immunity, host defense, and immunopathologyAdvances in Physiology Education, 2013
- Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteinsProceedings of the National Academy of Sciences, 2013
- Favipiravir (T-705), a novel viral RNA polymerase inhibitorAntiviral Research, 2013
- The 1918 Influenza Virus: A Killer Comes into ViewVirology, 2000